VYVGART is positioned to become the first biologic effective across all MG subtypes and a first-line option in CIDP. The upcoming FDA decision on May 10, 2026 for seronegative gMG and planned sBLA for oMG represent near-term catalysts. Real-world switching data de-risk commercial adoption in CIDP. Investors should monitor regulatory outcomes and upcoming Phase 3 data for empasiprubart in CIDP.
Price Chart
Executive Summary
argenx announced positive Phase 3 data from the ADAPT OCULUS and ADAPT SERON trials showing VYVGART's efficacy in ocular and seronegative myasthenia gravis, along with supportive data in CIDP. The company plans to submit a supplemental Biologics License Application (sBLA) for ocular MG and already has priority review for seronegative gMG, expanding VYVGART's potential market. Real-world data also support switching from IVIg to VYVGART Hytrulo in CIDP.
Key Facts
- Phase 3 ADAPT OCULUS study met primary endpoint (p=0.012) in ocular myasthenia gravis (oMG), showing statistically significant improvement in MGII PRO ocular scores at Week 4 vs placebo
- ADAPT SERON trial supports VYVGART's efficacy in AChR-Ab seronegative gMG (including MuSK+, LRP4+, triple seronegative), with FDA priority review granted and PDUFA date of May 10, 2026
- ADAPT Jr trial shows consistent MG-ADL improvements in adolescents with gMG
- ADHERE post hoc analysis shows 87.5% of treatment-naïve CIDP patients achieved early clinical benefit with VYVGART Hytrulo, median time to response 39.5 days
- Real-world data show 85.7% success rate switching from IVIg to VYVGART Hytrulo in 91 patients
- Planned sBLA submission to expand VYVGART label to oMG
Financial Impact
Significant revenue expansion potential as VYVGART gains broader label indications across multiple neuromuscular subtypes, including oMG (~20% of MG patients) and seronegative gMG
Risk Factors
- Regulatory delays or rejection of sBLA submissions despite positive data
- Competition from other biologics in neuromuscular indications
- Safety concerns with long-term use in broader populations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-045083 |
| Document: tm2612048d1_6k.htm | 0001104659-26-045083 |
| Document: 0001104659-26-045083-index-headers.html | 0001104659-26-045083 |
| Document: 0001104659-26-045083-index.html | 0001104659-26-045083 |
| Document: 0001104659-26-045083.txt | 0001104659-26-045083 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Institutional Cluster | $984.04 $995.77 | ▲ +1.19% | ▲ +1.69% | $918.23 (−6.69%) |
Aug 17, 2026 6w ago | 6-K | $987.84 $1,011.11 | ▲ +2.36% | ▲ +3.55% | $918.23 (−7.05%) |
Aug 6, 2026 8w ago | Press Release | $875.30 $856.94 | ▼ −2.10% | ▼ −3.31% | $918.23 (+4.91%) |
Jul 27, 2026 9w ago | 6-K | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 27, 2026 9w ago | Press Release | $888.82 $853.82 | ▼ −3.94% | ▼ −5.01% | $918.23 (+3.31%) |
Jul 23, 2026 10w ago | Press Release | $924.60 $872.58 | ▼ −5.63% | ▼ −6.10% | $918.23 (−0.69%) |
Jul 16, 2026 11w ago | Press Release | $857.97 $924.60 | ▲ +7.77% | ▲ +9.44% | $918.23 (+7.02%) |
Jun 23, 2026 14w ago | 6-K | $853.40 $912.46 | ▲ +6.92% | ▲ +5.91% | $918.23 (+7.60%) |
Jun 3, 2026 17w ago | 6-K | $813.14 $862.18 | ▲ +6.03% | ▲ +9.85% | $918.23 (+12.92%) |
May 8, 2026 20w ago | Press Release | $813.28 $776.26 | ▼ −4.55% | ▼ −4.47% | $918.23 (+12.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access